Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma

SIMPLE SUMMARY: Multiple myeloma is a deadly blood cancer, but fortunately drug development has substantially prolonged the lifespan of patients to average more than a decade after diagnosis with optimal therapy. As a result, the population of patients living with multiple myeloma has grown consider...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Lorraine N., Sherbenou, Daniel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038312/
https://www.ncbi.nlm.nih.gov/pubmed/33918370
http://dx.doi.org/10.3390/cancers13071686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038312/
https://www.ncbi.nlm.nih.gov/pubmed/33918370
http://dx.doi.org/10.3390/cancers13071686

Ejemplares similares